PURKINJE CELL CYTOPLASMIC ANTIBODY TYPE Tr DNER Test
Test Name: PURKINJE CELL CYTOPLASMIC ANTIBODY TYPE Tr DNER Test
Components: Price: 3040.0 AED
Sample Condition: 3 mL (2 mL min.) serum from 1 Red Top (No Additive) tube. Do not use SST gel barrier tubes OR 2 mL (1 mL min.) CSF in a sterile screw capped container. Ship refrigerated or frozen. Overnight fasting is preferred. Duly filled Test Send Out Consent Form is mandatory.
Report Delivery: Sample by 7th of the month; Report after 2-3 weeks
Method: CBA-IFA
Test Type: Disorders of Nervous System
Doctor: Neurologist
Test Department: OS
Pre Test Information: Overnight fasting is preferred. Duly filled Test Send Out Consent Form is mandatory.
Test Details:
The Purkinje cell cytoplasmic antibody type Tr (DNER) test is a diagnostic test used to detect the presence of antibodies against the Delta/Notch-like epidermal growth factor-related receptor (DNER) protein in the cytoplasm of Purkinje cells. Purkinje cells are a type of neuron found in the cerebellum, which plays a crucial role in motor coordination and balance.
Antibodies targeting the DNER protein can cause autoimmune-mediated damage to the Purkinje cells, leading to neurological symptoms. The test involves taking a blood sample from the patient and analyzing it in a laboratory. The sample is screened for the presence of antibodies against the DNER protein using various techniques, such as immunofluorescence or enzyme-linked immunosorbent assay (ELISA).
A positive result indicates the presence of anti-DNER antibodies, suggesting an autoimmune process affecting the cerebellum. The Purkinje cell cytoplasmic antibody type Tr (DNER) test is primarily used in the diagnosis of paraneoplastic cerebellar degeneration (PCD), a rare autoimmune disorder associated with certain types of cancer, particularly ovarian and breast cancer. PCD is characterized by the presence of anti-DNER antibodies and progressive cerebellar dysfunction.
Early detection and treatment of PCD are essential to prevent further neurological damage. The Purkinje cell cytoplasmic antibody type Tr (DNER) test, along with other clinical evaluations and imaging studies, can aid in the diagnosis and management of this condition.
Test Name | PURKINJE CELL CYTOPLASMIC ANTIBODY TYPE Tr DNER Test |
---|---|
Components | |
Price | 3040.0 AED |
Sample Condition | 3 mL (2 mL min.) serum from 1 Red Top (No Additive) tube. Do not use SST gel barrier tubes OR 2 mL (1 mL min.) CSF in a sterile screw capped container. Shiprefrigeratedorfrozen. Overnight fastingispreferred. Duly filled Test Send Out Consent Formis mandatory. |
Report Delivery | Sampleby7thofthemonth;Report after2??3weeks |
Method | CBA-IFA |
Test type | Disorders of Nervous System |
Doctor | Neurologist |
Test Department: | OS |
Pre Test Information | Overnight fastingispreferred. Duly filled Test Send Out Consent Formis mandatory. |
Test Details |
The Purkinje cell cytoplasmic antibody type Tr (DNER) test is a diagnostic test used to detect the presence of antibodies against the Delta/Notch-like epidermal growth factor-related receptor (DNER) protein in the cytoplasm of Purkinje cells. Purkinje cells are a type of neuron found in the cerebellum, which plays a crucial role in motor coordination and balance. Antibodies targeting the DNER protein can cause autoimmune-mediated damage to the Purkinje cells, leading to neurological symptoms. The test involves taking a blood sample from the patient and analyzing it in a laboratory. The sample is screened for the presence of antibodies against the DNER protein using various techniques, such as immunofluorescence or enzyme-linked immunosorbent assay (ELISA). A positive result indicates the presence of anti-DNER antibodies, suggesting an autoimmune process affecting the cerebellum. The Purkinje cell cytoplasmic antibody type Tr (DNER) test is primarily used in the diagnosis of paraneoplastic cerebellar degeneration (PCD), a rare autoimmune disorder associated with certain types of cancer, particularly ovarian and breast cancer. PCD is characterized by the presence of anti-DNER antibodies and progressive cerebellar dysfunction. Early detection and treatment of PCD are essential to prevent further neurological damage. The Purkinje cell cytoplasmic antibody type Tr (DNER) test, along with other clinical evaluations and imaging studies, can aid in the diagnosis and management of this condition. |